secwatch.observer — SEC 8-K summary
======================================

Issuer:     Incannex Healthcare Inc. (IXHL)
CIK:        0001873875
Form:       8-K
Filed at:   2026-05-12T11:30:21+00:00
Accession:  0001213900-26-054725
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X for Obstructive Sleep Apnea
--------------------------------------------------------------------------------

- Awarded 'Best New Technology Solution for Drug Development' in 10th annual MedTech Breakthrough Awards program.
- IHL-42X is a fixed-dose combination of dronabinol and acetazolamide targeting key drivers of OSA.
- Phase 2 RePOSA trial showed statistically significant reductions in AHI and improvements in oxygenation, sleep quality, and fatigue.
- CEO Joel Latham noted the award validates progress and potential to redefine OSA treatment paradigm.
- Recognition comes as Incannex advances IHL-42X toward late-stage development and explores strategic opportunities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026054725/0001213900-26-054725-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026054725/ea0289813-8k_incannex.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-054725

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer